摘要:
The present invention relates to novel octapeptide compounds of general formula (I): H-2-Nal 1-cyclo(Cys2-Tyr3-AA4-Lys5-Val6-Cys7)-Thr8-NH2. Since these products have a good affinity for certain somatostatin receptor subtypes, they are particularly advantageous for treating pathological states or diseases in which one (or more) somatostatin receptor(s) is (are) involved. These compounds furthermore have physiochemical properties that make it possible to envisage them in diverse solutions for the formulation of medicaments, for example as a pharmaceutically acceptable carrier. The invention also relates to pharmaceutical compositions containing said products and to the use thereof for the preparation of a medicament.
摘要:
The present invention relates to novel octapeptide compounds of general formula (I): H-2-Nal1-cyclo(Cys2-Tyr3-AA4-Lys5-Val6-Cys7)-Thr8-NH2. Since these products have a good affinity for certain somatostatin receptor subtypes, they are particularly advantageous for treating pathological states or diseases in which one (or more) somatostatin receptor(s) is (are) involved. These compounds furthermore have physiochemical properties that make it possible to envisage them in diverse solutions for the formulation of medicaments, for example as a pharmaceutically acceptable carrier. The invention also relates to pharmaceutical compositions containing said products and to the use thereof for the preparation of a medicament.
摘要:
The invention concerns hybrid nanoparticles containing: a nanosphere, of mean diameter included in the range from 2 to 9 nm, of which at least 90% by weight consists of Ln2O3 where Ln represents a rare earth, optionally doped with a rare earth or an actinide, or a mixture of rare earths, or a rare earth and actinide mixture, in which at least 50% of the metal ions are rare earth ions, a coating around the nanosphere chiefly consisting of functionalized polysiloxane, having a mean thickness included in the range from 0.5 to 10 nm, preferably greater than 2 nm and no more than 10 nm, and at least one biological ligand grafted by covalent bonding to the polysiloxane coating and their method of preparation.
摘要翻译:本发明涉及包含纳米球的混合纳米颗粒,其平均直径包括在2至9nm的范围内,其中至少90重量%由Ln 2 O 3组成,其中Ln表示稀土,任选地掺杂有稀土或锕系元素 ,或稀土或稀土和锕系混合物的混合物,其中至少50%的金属离子是稀土离子,主要由官能化聚硅氧烷组成的纳米球周围的涂层,其平均厚度包括在该范围内 0.5至10nm,优选大于2nm且不超过10nm,以及至少一种通过与聚硅氧烷涂层共价键接枝的生物配体及其制备方法。
摘要:
The invention relates to the use of nanoparticles with dimensions comprised between 1 and 50 nm, at least one portion of which consists of at least one oxide and/or one oxohydroxide of at least one lanthanide, said nanoparticles: either consisting of at least one oxide and/or one oxohydroxide of at least one lanthanide, or in the form of nanoparticles comprising a core consisting of at least one oxide and/or one oxohydroxide of at least one lanthanide, and a coating consisting of polysiloxane, with possibly organic molecules grafted at the surface or comprised inside it, as a radio-sensitizing agent in the making of an injectable composition intended to improve the efficiency of the treatment of a tumor by X or gamma irradiations. It also relates to nanoparticles particularly suitable for the use above, consisting of a core consisting of at least one oxide and/or one oxohydroxide of at least one lanthanide and of a coating in polysiloxane comprising 1 to 5 silicon atoms per lanthanide and at least 10% of the silicon atoms of which are bound to hydrophilic organic molecules with molar masses of less than 450 g/mol.
摘要:
The invention concerns an electrowetting device comprising first and second immiscible fluids, the liquids being sealed within a structure comprising a cap portion, a base portion, a gasket formed of a first material positioned between a first contact surface on said cap portion and a second contact surface on said base portion, and a first film formed of a second material between said gasket and one of said first contact surface and said second contact surface.
摘要:
The invention relates to novel biocompatible hybrid nanoparticles of very small size, useful in particular for diagnostics and/or therapy.The purpose of the invention is to offer novel nanoparticles which are useful in particular as contrast agents in imaging (e.g. MRI) and/or in other diagnostic techniques and/or as therapeutic agents, which give better performance than the known nanoparticles of the same type and which combine both a small size (for example less than 20 nm) and a high loading with metals (e.g. rare earths), in particular so as to have, in imaging (e.g. MRI), strong intensification and a correct response (increased relaxivity) at high frequencies.Thus, the nanoparticles according to the invention, with diameter d1 between 1 and 20 nm, each comprise a polyorganosiloxane (POS) matrix including gadolinium cations optionally associated with doping cations; a chelating graft C1 DTPABA (diethylenetriaminepentaacetic acid bisanhydride) bound to the POS matrix by an —Si—C— covalent bond, and present in sufficient quantity to be able to complex all the gadolinium cations; and optionally another functionalizing graft Gf* bound to the POS matrix by an —Si—C— covalent bond (where Gf* can be derived from a hydrophilic compound (PEG); from a compound having an active ingredient PA1; from a targeting compound; from a luminescent compound (fluorescein).The method for the production of these nanoparticles and the applications thereof in imaging and in therapy also form part of the invention.